Overview

EGFR-targeted Therapy for Gastric Cancer

Status:
Recruiting

Trial end date:
2023-12-31

Target enrollment:

Participant gender:

Summary

Based on targeted NGS panel results, metastatic gastric cancer patients with gene amplifications will receive either anti-EGFR antibody (GC-1118) in combination with weekly paclitaxel as a second-line therapy.

Phase:

Phase 2

Details

Lead Sponsor:

National Cancer Center, Korea

Collaborator:

Korean Cancer Study Group

Treatments:

Albumin-Bound Paclitaxel
Antibodies
Immunoglobulins
Paclitaxel